Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05890872 · ClinicalTrials.gov registry record · NA
Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer
A NA study, sponsored by Galvanize Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT05890872: Completed NA study, sponsored by Galvanize Therapeutics.
NCT05890872 is a NA study that has completed, run by Galvanize Therapeutics. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05890872, a NA study, has completed, sponsored by Galvanize Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
Primary Outcome
The rate of study device-related and/or PEF procedure-related serious adverse events (SAEs)
Interventions
- DEVICE Aliya Pulsed Electric Fields (PEF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2025-08-13 |
| Phase | NA |
What the finished NCT05890872 record still lists
NCT05890872 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Aliya Pulsed Electric Fields (PEF) is the first listed.
NCT05890872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05890872 about?
NCT05890872 is a clinical study titled "Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer". The goal of this clinical trial is to evaluate safety of delivering Aliya PEF in patients with metastatic cancer within the lungs or stage IV non-small cell lung cancer (NSCLC) who are treatment-naïve and indicated for first-line standard of care (SOC) cancer therapy.
What is the current status of trial NCT05890872?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2023-09-06. Estimated completion is 2025-08-13.
What interventions are being tested in trial NCT05890872?
The interventions under investigation include: Aliya Pulsed Electric Fields (PEF) (DEVICE).
Who is sponsoring clinical trial NCT05890872?
This trial is sponsored by Galvanize Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05890872's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI